HOME >> MEDICINE >> NEWS
Antiplatelet drug found to reduce risk of recurrent heart attacks and stroke is cost-effective

ORLANDO -- The antiplatelet medicine clopidogrel is not only effective in reducing the risk of recurrent heart attack and stroke, it is also extremely cost-effective, according to data presented today by researchers from Emory University at the American Heart Association's Scientific Sessions.

"We have three separate investigations showing uniform results in both the short and long-term use of clopidogrel. Specifically, the use of clopidogrel in addition to aspirin produces a significant risk reduction in recurrent heart attack, stroke or cardiovascular death," says William Weintraub, M.D. FACC, Director, Emory Center for Outcomes Research in the Division of Cardiology, Department of Medicine, Emory University School of Medicine, who presented the data. "The study findings and the cost-effectiveness data suggest that at least one year of therapy with clopidogrel is an attractive value. In fact, we believe it should be the standard of care for this patient population."

The Emory University investigators analyzed the drug's cost-effectiveness ratio in two major clinical studies -- the CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial and the CREDO (Clopidogrel for the Reduction of Events During Observation) trial -- as well as a substudy of CURE, called PCI-CURE . Cost-effectiveness ratio is the incremental cost of using an intervention to obtain a unit of effectiveness (such as dollars per life-year gained) compared to another treatment or no treatment.

Based on CURE, the Emory researchers found that the cost-effectiveness ratio was $6,173 per life year gained. PCI-CURE, which evaluated people who received clopidogrel for up to one year after having an angioplasty or stent, demonstrated a cost-effectiveness ratio of $5,910 per life year gained. In CREDO, patients were given a dose of clopidogrel before having an angioplasty or stenting procedures and continued on clopidogrel therapy for up to one year. The cost-effect
'"/>

Contact: Sherry Baker
emoryheartnews@aol.com
404-377-1398
Emory University Health Sciences Center
12-Nov-2003


Page: 1 2

Related medicine news :

1. Antiplatelet drugs: comparison of clopidogrel with aspirin
2. Acupuncture found to lower elevations in blood pressure
3. Proteins found in urine of pregnant women could help diagnose preeclampsia
4. Potential drug target for treating cocaine abuse found
5. Similar results found in both older and younger patients undergoing weight-loss surgery
6. Infectious agent linked to mad cow disease found in organs other than the brain
7. Generation gap found in chronic pain
8. A site for sore eyes: New target for allergies found under the eyelid
9. Chemicals found in cherries may help fight diabetes
10. Thanks for the memories: cinematic portrayal of amnesia is profoundly misleading
11. Very high prevalence of virus linked to cervical cancer found in adolescent women

Post Your Comments:
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency Foundation (IDF) ... community using its IDF ePHR, an electronic personal health record powered by Get ... easily track their health information, including symptoms, diagnoses, medications, infusions and other critical ...
(Date:7/7/2015)... ... 07, 2015 , ... Parents and guardians of teenagers or young adults will ... holistic treatment center for drug and alcohol abuse located in Southwest Michigan. A recently ... shown a significant increase in the “club drug” use among high school seniors. The ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... of telemedicine programs in communities throughout Georgia, announces the launch of the first ... rural communities of Hancock County, GA. The new program will not only provide ...
(Date:7/7/2015)... NH (PRWEB) , ... July ... ... integrated, full-service public relations, marketing, and creative design firm, today announced that ... regional public relations and social media campaign, content strategy, and marketing launch ...
(Date:7/7/2015)... Horsham, PA (PRWEB) , ... July 07, 2015 ... ... seasoned financial executive Ellen Purdy as the company’s new Chief Financial Officer, effective ... financial and leadership experience in companies ranging from a multi-billion dollar, global chemical ...
Breaking Medicine News(10 mins):Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:Office Practicum Announces new CFO 2
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
(Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
Cached News: